The impact on outcome of the number of mutations detected by MS at baseline for CP-CML patients without the T315I mutation. CP-CML patients without T315I by MS were grouped according to the number of mutations detected by MS before commencing ponatinib therapy: no mutation, n = 112; 1 mutation, n = 39; >1 mutation, n = 17. (A) MCyR. (B) CCyR. (C) MMR. (D) FFS. (E) PFS.